Summer Sale
50% off Premium Yearly
00days
00hrs
00mins
00secs
NYSE:PFE
Pfizer Inc (PFE)
26.19
+0.59 (2.30%)
as of Jun 11, 2026, 8:09:11 pm Market Open.
322 watching
Financials 
Technical Analysis 0
DON'T BUY
He stays away from drug companies, always forced to do acquisitions. Costly and competitive business. Pressures from government. Boost from pandemic, and this will continue. Reasonable valuation. He prefers medical devices, where you don't need a PhD to understand what's coming next. Attractive yield about 3%.
biotechnologypharmaceutical
DON'T BUY
Has tended to peak out at 4x book value, around $50. Vaccine potential has petered out. FMV potential is 55% higher than current price. More likely to have a further setback, with $37-38 as his downside target. The stock's already given at the office and it's not prepared to give at home.
biotechnologypharmaceutical
BUY
It looks good it will get FDA approval for a Covid vaccine for children. Any good news here will help PFE. He's owned this for a while. The current pullback is a buying opportunity.
Andrew PyleOwned
biotechnologypharmaceutical
BUY
Many reasons to like this including booster shots which will help shares (though Moderna will benefit more). This has pulled back a but, she likes it here. Has value.
biotechnologypharmaceutical
BUY
It's been on a hot run. The Delta variant gives them a huge tailwind, because Washington is about to mandate Covid booster shots. Pfizer needs it, because they're about to lose the patents on some of their major drugs. Annual booster shots would give Pfizer a giant revenue stream. Shares are up 22% in the past month.
biotechnologypharmaceutical
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPAST TOP PICK
(A Top Pick Sep 24/20, Up 39%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE is progressing well. We now recommend trailing up the stop (from $33) to $42. If triggered this would all but guarantee a investment return over 17%, when including the previous recommendation to cover half.
biotechnologypharmaceutical
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
